Literature DB >> 20148532

Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.

Jelena Klawitter1, Sven Gottschalk, Carsten Hainz, Dieter Leibfritz, Uwe Christians, Natalie J Serkova.   

Abstract

Coadministration of the calcineurin inhibitor cyclosporine (CsA) and the mTOR inhibitors sirolimus (SRL) or everolimus (RAD) increases the efficacy of immunosuppression after organ transplantation. Neurotoxicity of CsA is a major clinical problem. Our goal was to assess the effects of CsA, SRL, and RAD on brain cell metabolism. The studies included the comparison of immunosuppressant-mediated effects on glucose metabolism, energy production, and reactive oxygen species (ROS) formation in perfused rat brain slices, primary rat astrocytes, and C6 glioma cells. In brain slices and astrocytes, CsA inhibited Krebs cycle metabolism, while activating anaerobic glycolysis, most likely to compensate for the inhibition of mitochondrial energy production. SRL and RAD inhibited cytosolic glycolysis but did not cause changes in mitochondrial energy production. CsA + SRL inhibited Krebs cycle and glycolysis, thus reducing the ability of the cell to compensate for the negative effects of CsA on mitochondrial nucleoside triphosphate synthesis. In contrast to SRL at the concentrations tested, RAD reduced the CsA-induced ROS formation and antagonized CsA-induced effects on glucose and energy metabolism. Surprisingly, in C6 cells, SRL and RAD exposure resulted in high ROS concentrations without significant impairment of cell metabolism. Our results suggested that SRL enhances CsA-induced ROS formation and negative metabolic effects in brain cells, while RAD seems to antagonize the CsA effects. However, the three models showed different metabolic responses when challenged with the study drugs. In contrast to SRL, RAD enhances ROS formation in C6 glioma cells but has only minor effects on normal rat brain tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148532      PMCID: PMC2841482          DOI: 10.1021/tx900351q

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  61 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  Akt-dependent transformation: there is more to growth than just surviving.

Authors:  David R Plas; Craig B Thompson
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 3.  mTOR and cancer therapy.

Authors:  J B Easton; P J Houghton
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

4.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

Authors:  Dunyaporn Trachootham; Yan Zhou; Hui Zhang; Yusuke Demizu; Zhao Chen; Helene Pelicano; Paul J Chiao; Geetha Achanta; Ralph B Arlinghaus; Jinsong Liu; Peng Huang
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

5.  Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy.

Authors:  N Serkova; U Christians; U Flögel; J Pfeuffer; D Leibfritz
Journal:  Chem Res Toxicol       Date:  1997-12       Impact factor: 3.739

6.  Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood.

Authors:  Natalie J Serkova; Uwe Christians
Journal:  Ther Drug Monit       Date:  2005-12       Impact factor: 3.681

7.  The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.

Authors:  Anita B Hjelmeland; Kathryn P Lattimore; Brian E Fee; Qing Shi; Sarah Wickman; Stephen T Keir; Mark D Hjelmeland; David Batt; Darell D Bigner; Henry S Friedman; Jeremy N Rich
Journal:  Mol Cancer Ther       Date:  2007-08-31       Impact factor: 6.261

Review 8.  Sirolimus in renal transplantation.

Authors:  Christian Morath; Wolfgang Arns; Vedat Schwenger; Arianeb Mehrabi; Hamidreza Fonouni; Jan Schmidt; Martin Zeier
Journal:  Nephrol Dial Transplant       Date:  2007-09       Impact factor: 5.992

Review 9.  NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology.

Authors:  Muireann Coen; Elaine Holmes; John C Lindon; Jeremy K Nicholson
Journal:  Chem Res Toxicol       Date:  2008-01-03       Impact factor: 3.739

10.  Vulnerability of glial cells to hydrogen peroxide in cultured hippocampal slices.

Authors:  Chris J Feeney; Marina V Frantseva; Peter L Carlen; Peter S Pennefather; Natalya Shulyakova; Chloe Shniffer; Linda R Mills
Journal:  Brain Res       Date:  2008-01-03       Impact factor: 3.252

View more
  18 in total

1.  Altered metabolomic profiles may be associated with sevoflurane-induced neurotoxicity in neonatal rats.

Authors:  Bin Liu; Yuechao Gu; Hongyan Xiao; Xi Lei; Weimin Liang; Jun Zhang
Journal:  Neurochem Res       Date:  2015-02-07       Impact factor: 3.996

2.  Effect of dietary sodium restriction on human urinary metabolomic profiles.

Authors:  Kristen L Jablonski; Jelena Klawitter; Michel Chonchol; Candace J Bassett; Matthew L Racine; Douglas R Seals
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 8.237

3.  Androgen and PARP-1 regulation of TRPM2 channels after ischemic injury.

Authors:  Takeru Shimizu; Tara A Macey; Nidia Quillinan; Jelena Klawitter; Anne-Laure L Perraud; Richard J Traystman; Paco S Herson
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-26       Impact factor: 6.200

4.  Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Authors:  Jelena Klawitter; Jost Klawitter; Volker Schmitz; Nina Brunner; Amanda Crunk; Kyler Corby; Jamie Bendrick-Peart; Dieter Leibfritz; Charles L Edelstein; Joshua M Thurman; Uwe Christians
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

Review 5.  Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.

Authors:  Patrick J Ronan; Sarah A Flynn; Thomas P Beresford
Journal:  Prog Mol Biol Transl Sci       Date:  2019-08-12       Impact factor: 3.622

Review 6.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 7.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 8.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

Review 9.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

10.  Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat.

Authors:  Rahul Bohra; Wenzel Schöning; Jelena Klawitter; Nina Brunner; Volker Schmitz; Touraj Shokati; Ryan Lawrence; Maria Fernanda Arbelaez; Björn Schniedewind; Uwe Christians; Jost Klawitter
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.